Vicore Pharma Holding AB (publ) - Asset Resilience Ratio

Latest as of December 2025: 48.38%

Vicore Pharma Holding AB (publ) (VICO) has an Asset Resilience Ratio of 48.38% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VICO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr590.06 Million
≈ $63.50 Million USD Cash + Short-term Investments

Total Assets

Skr1.22 Billion
≈ $131.25 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Vicore Pharma Holding AB (publ)'s Asset Resilience Ratio has changed over time. See VICO net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Vicore Pharma Holding AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vicore Pharma Holding AB (publ) (VICO) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr0.00 0%
Short-term Investments Skr590.06 Million 48.38%
Total Liquid Assets Skr590.06 Million 48.38%

Asset Resilience Insights

  • Very High Liquidity: Vicore Pharma Holding AB (publ) maintains exceptional liquid asset reserves at 48.38% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Vicore Pharma Holding AB (publ) Industry Peers by Asset Resilience Ratio

Compare Vicore Pharma Holding AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Vicore Pharma Holding AB (publ) (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Vicore Pharma Holding AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 48.38% Skr590.06 Million
≈ $63.50 Million
Skr1.22 Billion
≈ $131.25 Million
--
2024-12-31 0.00% Skr0.00
≈ $0.00
Skr1.20 Billion
≈ $129.47 Million
--
2023-12-31 29.94% Skr149.04 Million
≈ $16.04 Million
Skr497.84 Million
≈ $53.58 Million
+28.48pp
2022-12-31 1.46% Skr4.94 Million
≈ $531.62K
Skr338.01 Million
≈ $36.37 Million
-15.61pp
2021-12-31 17.07% Skr77.00 Million
≈ $8.29 Million
Skr451.17 Million
≈ $48.55 Million
-0.15pp
2020-12-31 17.22% Skr70.00 Million
≈ $7.53 Million
Skr406.51 Million
≈ $43.75 Million
-5.35pp
2019-12-31 22.57% Skr77.00 Million
≈ $8.29 Million
Skr341.11 Million
≈ $36.71 Million
+22.57pp
2018-12-31 0.01% Skr21.00K
≈ $2.26K
Skr301.60 Million
≈ $32.46 Million
--
pp = percentage points

About Vicore Pharma Holding AB (publ)

ST:VICO Sweden Biotechnology
Market Cap
$336.29 Million
Skr3.12 Billion SEK
Market Cap Rank
#14390 Global
#230 in Sweden
Share Price
Skr11.10
Change (1 day)
+2.02%
52-Week Range
Skr7.35 - Skr13.34
All Time High
Skr37.60
About

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more